T cell numbers relate to bone involvement in Gaucher disease

Blood Cells, Molecules, and Diseases

Volumn 25, Issue 2, 1999, Pages 130-138

  Lacerda, Lucia ^a   Arosa, Fernando A ^a   Lacerda, Rosa ^b   Cabeda, José ^b,c   Porto, Graça ^b,c   Amaral, Olga ^a   Fortuna, Ana ^d   Pinto, Rui ^a   Oliveira, Pedro ^e   McLaren, Christine E ^f   Miranda, Clara Sá ^a   De Sousa, Maria ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c HOSPITAL DE SANTO ANTÓNIO   (Portugal)

^d Institute of Genetics Jacinto Magalhães   (Portugal)

^e UNIVERSITY OF MINHO   (Portugal)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CD8 positive T lymphocytes and bone pathology; Chitotriosidase; Gaucher's disease; Tartrate resistant acid phosphatase

Indexed keywords

ACID PHOSPHATASE;

ADOLESCENT; ADULT; ARTICLE; BONE DISEASE; BONE NECROSIS; CHILD; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; DISEASE SEVERITY; FEMALE; GAUCHER DISEASE; GENE MUTATION; GENOTYPE; HELPER CELL; HOMOZYGOSITY; HUMAN; MALE; OSTEOCLAST; OSTEOPENIA; PHENOTYPE; PRIORITY JOURNAL; SPLENECTOMY; T LYMPHOCYTE SUBPOPULATION;

EID: 0033061572     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1006/bcmd.1999.0237     Document Type: Article

References (31)

1. Beutler E, Grabowski G. Gaucher disease. Scriver C, Beaudet A, Sly W, Valle D. The Metabolic and Molecular Bases of Inherited Disease on CD-ROM. 1997;McGraw-Hill, Inc. New York.
2. Lacerda L, Amaral O, Pinto R, Oliveira P, Aerts J, Sá Miranda M C. Gaucher disease: N370S glucocerebrosidase gene frequency in the Portuguese population. Clin Genet. 45:1994;298-300.
3. Cox T, Schofield J. Gaucher's disease: clinical features and natural history. Baillières Clin Haematol. 10:1997;657-689.
4. Rosenthal, D. Quantitative imaging of the skeleton in patients with Gaucher disease, Gaucher Clinical Perspectives3:4-8, 1995.
5. Siffert, R, Platt, G. Gaucher disease: Orthopedic considerations. In: Desnick, R, Gatt, S, Grabowski, G, eds. Gaucher disease. A Century of Delineation and ResearchNew York, Alan R Liss, pp. 617-626, 1982.
6. Barton N, Brady R, Dambrosia. Replacement therapy for inherited enzyme deficiency: macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med. 324:1991;1464-1470.
7. Elstein D, Hadas-Halpern I, Itzchaki M, Lahad A, Abrahamov A, Zimran A. Effect of low-dose enzyme replacement therapy on bones in Gaucher disease patients with severe skeletal involvement. Blood Cells Mol Dis. 22:1996;104-111.
8. Mistry P, Wraight E, Cox T. Therapeutic delivery of proteins to macrophages: implications for treatment of Gaucher's disease. Lancet. 348:1996;1555-1559.
9. Beutler, E, Kuhl, W, Vaughan, L, M. Failure of alglucerase infused into Gaucher disease patients to localize in marrow macrophages. Mol Med1:320-324.
10. John V, Hock J, Short L, Glasebrook A, Sells, Galvin R. A role for CD8+ T lymphocytes in osteoclast differentiation in vitro. Endocrinology. 137:1996;2457-2463.
11. Horwood N, Udagawa N, Elliott J. Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colony-stimulating factor. J Clin Invest. 101:1998;595-603.
12. Hollak C, van Weely S, van Oers M, Aerts J. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest. 93:1994;1288-1292.
13. Aerts J, Hollak C. Plasma and metabolic abnormalities in Gaucher's disease. Baillières Clin Haematol. 10:1997;691-709.
14. Ek-Rylander B, Bill P, Norgard M, Nilsson S, Andersson G. Cloning, sequence, and developmental expression of type 5, tartrate-resistant, acid phosphatase of rat bone. J. Biol Chem. 266:1991;24684-24689.
15. Ek-Rylander B, Flores M, Wendel M, Heinegard D, Andersson G. Dephosphorylation of osteopondin and bone sialoprotein by osteoclastic tartrate-resistant acid-phosphatase. Modulation of osteoclast adhesion in vitro. J Biol Chem. 269:1994;14853-14856.
16. Sá Miranda, M, C, Aerts, J, M, Pinto, R, et al 1990. Activity of glucocerebrosidase in extracts of different cell types from type 1 Gaucher disease patients. Clin Genet38:218-227, 1990.
17. Amaral O, Lacerda L, Santos R, Pinto R, Aerts J, Sá Miranda M C. Type I Gaucher disease: molecular, biochemical and clinical characterization of patients from Northern Portugal. Biochem Med Metab Biol. 49:1993;97-107.
18. Amaral O, Pinto E, Fortuna M, Lacerda L, Sá Miranda M C. Type 1 Gaucher disease: identification of N396T and prevalence of glucocerebrosidase mutations in the Portuguese. Hum Mutat. 8:1996;280-281.
19. Hermann G, Goldblatt J, Levy R, Goldsmith S J, Desnick R J, Grabowski G A. Gaucher's disease type 1: assessment of bone involvement by CT and scintigraphy. Am J Rad. 147:1986;943-948.
20. Zimran A, Gross E, West C, Sorge J, Kubitz M, Beutler E. Prediction of severity of Gaucher's disease by identification of mutations at DNA level. Lancet. 2:1989;349-352.
21. Furbish F, Steer C, Krett N, Barranger J. Uptake and distribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylation. Biochem. Biophys. Acta. 673:1981;425-434.
22. Magalhães J, Pinto R, Lemos M, Sá Miranda M, Poenaru L. Age dependency of serum acid phosphatase in controls and Gaucher patients. Enzyme. 32:1984;95-99.
23. Arosa, F, da Silva, A, Godinho, et al. 1994. Decreased CD8-p56lck activity in peripheral blood T-lymphocytes from patients with hereditary haemochromatosis. Scand J Immunol39:426-432, 1994.
24. McLaren C E, Kambour E L, McLachlan G J, Lukaski H C, Li X, Brittenham G M, McLaren G D. Multiple linear regression and finite mixture distribution modeling for sequential analysis of hematological data. Stat Med. 1999.
25. Furnival G M, Wilson R W Jr. Regression by leaps and bounds. Technometrics. 16:1974;599-511.
26. Eubanks R L. Spline Smoothing and Nonparametric Regression. 1988;Marcel Deker, Inc. New York. p. 438.
27. Consolini R, Cini P, Cei B, Botton E. Thymic dysfunctioning histiocytosis X. Am J Pediatr Hematol/Oncol. 9:1987;146-148.
28. + peripheral blood T lymphocytes in rapidly progressive periodontitis. Arch Oral Biol. 40:1995;605-608.
29. Philipart N, Menkes J. Characterization of the main splenic glycolipids in Gaucher's disease: Evidence for the site of metabolic block. Biochem Biophys Res Commun. 15:1964;551-555.
30. Grassi F, Lopalco L, Lanza P. Chemical residues of ganglioside molecules involved in interactions with lymphocyte surface targets leading to CD4 masking and inhibition of mitogenic proliferation. Eur J Immunol. 20:1990;145-150.
31. Saggioro D, Sorio C, Calderazzo. Mechanism of action of the monosialoganglioside GM1 as a modulator of CD4 expression. J Biol Chem. 268:1993;1368-1375.